Compare SAR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAR | MNPR |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.6M | 368.9M |
| IPO Year | N/A | 2019 |
| Metric | SAR | MNPR |
|---|---|---|
| Price | $22.36 | $59.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $23.75 | ★ $107.00 |
| AVG Volume (30 Days) | 87.5K | ★ 168.5K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.34% | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.39 | N/A |
| P/E Ratio | $9.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.78 | $29.18 |
| 52 Week High | $25.64 | $105.00 |
| Indicator | SAR | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 48.81 |
| Support Level | $21.58 | $51.32 |
| Resistance Level | $22.82 | $61.51 |
| Average True Range (ATR) | 0.39 | 4.78 |
| MACD | 0.02 | -0.49 |
| Stochastic Oscillator | 50.91 | 39.71 |
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.